Hypha Labs, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- A. Stone Douglass
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 5940 S. Rainbow Boulevard Las Vegas NV United States of America 89118
- IPO Date
- Aug 13, 2012
- CIK
- 0001502966
- Website
- hyphalabs.com
- Similar Companies
- Business
- Hypha Labs, Inc. is a biotechnology company focused on functional mushroom sciences and the development of proprietary production platforms for active mushroom-derived ingredients, including its Mushroom Accelerator technology and MicroPearls suite of products, with operations anchored in Las Vegas, Nevada, and expanding manufacturing and R&D capabilities to support in-home and commercial applications; the company was founded in 2020 and is headquartered in Las Vegas, Nevada, United States, pursuing partnerships and strategic alliances to advance mushroom-based therapeutics and nutraceuticals, while targeting end-use markets in health, wellness, and diagnostics research. Hypha Labs manufactures and supplies functional mushroom bioreactor systems for accelerated cultivation; produces and licenses MicroPearls edible and pharmaceutical-grade mushroom ingredients; provides analytical testing services and research collaborations; engages in ongoing product development, including enhancements to analytical instrumentation and process automation; and seeks to scale domestic and international manufacturing via outside-contract manufacturers and potential overseas facilities to reduce cost and increase supply chain resilience. The company’s activities span research and development, clinical and preclinical exploration, product formulation and licensing, and collaborative ventures with academic and industry partners to advance mycology-based science and mushroom-derived products. Core offerings include Hypha Micropearl bioreactors, Mushroom Accelerator systems, MicroPearls ingredient lines, analytical testing services, and research collaboration programs, delivered across commercial, pharmaceutical, and consumer health segments in North America, Europe, and select partner markets. Hypha Labs maintains a forward-looking strategy to broaden its platform through acquisitions, partnerships, and potential new product launches aimed at expanding application areas such as diagnostics, nutraceuticals, and personalized mushroom-based therapies. The company emphasizes intellectual property development around its bioreactor technology, functional mushroom extraction methods, and standardized production workflows to support scalable manufacturing and consistent product quality for customers and collaborators worldwide.
Hypha Labs (OTCQB:FUNI) Sees State-by-State Psilocybin Reform Creating the Next Major Growth Opportunity
Hypha Labs Highlights Parallels Between Emerging Psychedelic Industry and Early Cannabis Market Expansion
Trump Psychedelic Executive Order Accelerates Industry Growth
Hypha Labs, Inc. (OTCQB:FUNI) Announces Partnership with Mycology Resources, LLC
Hypha Labs and Tryptomics Launch Phase II of Strategic Partnership, Pairing Patented Mushroom Accelerator(TM) with World-Class Internal Quality Control & Fungal Genomics
Hypha Labs and Automated Technical Services (ATS) Enter into Agreement to Scale its Mushroom Accelerator Technology for Commercial Nutraceutical Manufacturing
Hypha Labs Expands List of Functional Mushrooms Able to be Produced in its Revolutionary Mushroom Accelerator
Hypha Labs Provides Shareholder Update
Hypha Labs Files New Patent Application for Its Suite of Artificial Intelligence (AI) Techniques for Its Mushroom Accelerator
Hypha Labs Files Multiple Additional Patents for its Ground Breaking Mushroom Accelerator
Emerging Markets Report: A Milestone for Mycelium
Hypha Labs Acquires State-of-the-Art HPLC Analytic Machine and Partners with Lucidity Systems for Advanced Autosampler Upgrade
New Mexico Governor Signs Bill Allowing for Psilocybin Use
Hypha Laboratories Retains Stockhouse for International Awareness Campaign
Emerging Markets Report: Breakthroughs & Bureaucracy
Hypha Laboratories Reports Significant Breakthrough for MicroPearls(TM) Yields
Hypha Laboratories Applauds Call for Regulatory Changes for Functional Mushrooms
Hypha Laboratories Announces Completion of Phase 1 of Its State-of-the-Art Facility and Arrival of V5 Working MicroPearls(TM) Prototypes
Emerging Markets Report: A Mushroom Monster in the Making
Hypha Laboratories Establishes Scientific and Cultural Advisory Board, Adds William Padilla-Brown